

6 August 2021

ASX Code: MXC

LSE Code: MXC

MGC Pharma General Meeting Information and Webinar

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to advise that it will be live streaming the Shareholder's General Meeting to be held at 1202 Hay Street West Perth on **Thursday 12 August 2021 at 4.00pm AWST.**

The formal business of the GM will be hosted by MGC Pharma's Chairman, Mr Brett Mitchell, with other board members attending remotely by video link.

To register for the Webinar, please use the link below:

https://us02web.zoom.us/webinar/register/WN_PavB2esgQDuOZWl6f5NV-w

Upon registration to the Webinar participants are welcome to submit questions to the Company. The Board will endeavour to answer questions relevant to the business of the meeting, as well as questions regarding the Company's operations. Please note that the video stream is view only and will not facilitate the casting of votes on Resolutions before the meeting.

Shareholders are strongly encouraged to vote prior to the meeting by following the instructions provided to them on the recently distributed proxy form.

Shareholders may also lodge their proxy votes online by following the steps below:

- Go to www.investorvote.com.au
- Enter the 6-digit control number: **185353**
- You will then need your HIN/SRN and postcode to log-on

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

MGC Pharmaceuticals Ltd
David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels

